Eurofins CDMO specialises in API and drug substance development for complex small molecule programmes, ensuring seamless transitions from preclinical, clinical to market with comprehensive support at every phase.

With 20+ years of experience and 13 global facilities, we deliver wide-ranging drug development solutions from early API research to finished products.

Our integrated Solid State Research and Development ensures a quality by design approach throughout API and drug product development and manufacturing.